Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

(TTXVN/Vietnam+) 09:51 23/10/2020

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

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